Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

(TTXVN/Vietnam+) 09:51 23/10/2020

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

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